Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

(TTXVN/Vietnam+) 09:51 23/10/2020

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

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